Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

(TTXVN/Vietnam+) 09:51 23/10/2020

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

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